Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

(TTXVN/Vietnam+) 09:51 23/10/2020

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

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